Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group said on Thursday after business leaders, including CEO of obesity drugmaker Novo Nordisk,

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday.

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations for a possible trade conflict with the United States over Greenland with Denmark's Prime Minister Mette Frederiksen on Thursday.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss potential measures by the incoming Trump administration amid escalating tensions over Greenland.

Denmark’s Prime Minister Mette Frederiksen has called the country’s business leaders to a meeting on Thursday after US President-elect Donald Trump last week threatened military or economic action such as tariffs to take control of Greenland.

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO stock as a strong buy.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).